NXL Nexalin Technology, Inc. - 8-K

Item 7.01

Regulation FD Disclosure.

On February 24, 2026, Nexalin
Technology, Inc. (the “Company”) issued a press release announcing the advancement of its planned pivotal clinical trial
evaluating the HALO™ Clarity device for the treatment of moderate to severe insomnia, designed to support the Company’s planned
de novo submission to the U.S. Food and Drug Administration. The study will be conducted in collaboration with Lindus Health. A copy
of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information furnished in this Item
7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange
Act, except as shall be expressly set forth by specific reference in such filing.

Cautionary Note Regarding Forward-Looking Statements

This
Current Report on Form 8-K and the attached press release contain forward-looking statements within the meaning of Section 27A of the
Securities Act and Section 21E of the Exchange Act. These forward-looking statements include, but are not limited to, statements regarding
the Company’s planned clinical trial, the timing and results thereof, the Company’s regulatory strategy, and its ability
to obtain FDA clearance or approval. Forward-looking statements are based on current expectations and are subject to risks and uncertainties
that could cause actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such
differences include, but are not limited to, risks related to clinical trial design, execution, and results; regulatory uncertainties;
reliance on third-party collaborators; and other risks described in the Company’s filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q. The Company
undertakes no obligation to update any forward-looking statements, except as required by law.

1

Item 9.01

Financial Statements and Exhibits.

Exhibit No.

Description

99.1

Press Release, dated February 24, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

2